Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.80 Average Price Target from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $22.80.

A number of brokerages have issued reports on ZVRA. Cantor Fitzgerald decreased their price objective on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Tuesday, October 14th. Finally, Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, November 6th.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $8.12 on Friday. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16. The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46. The firm’s fifty day moving average is $9.58 and its 200 day moving average is $9.72. The company has a market cap of $457.16 million, a price-to-earnings ratio of 17.28 and a beta of 1.01.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. The firm had revenue of $26.06 million for the quarter, compared to the consensus estimate of $26.64 million. Sell-side analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Neil F. Mcfarlane sold 19,500 shares of the stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the sale, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at $2,402,213.12. This represents a 8.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in shares of Zevra Therapeutics by 2.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock worth $1,148,000 after acquiring an additional 3,827 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Zevra Therapeutics in the first quarter worth $1,052,000. EntryPoint Capital LLC lifted its position in shares of Zevra Therapeutics by 53.8% during the first quarter. EntryPoint Capital LLC now owns 40,675 shares of the company’s stock worth $305,000 after purchasing an additional 14,225 shares during the last quarter. Stonepine Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 8.8% during the first quarter. Stonepine Capital Management LLC now owns 650,000 shares of the company’s stock valued at $4,868,000 after purchasing an additional 52,300 shares during the period. Finally, Velan Capital Investment Management LP boosted its stake in shares of Zevra Therapeutics by 121.7% during the first quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company’s stock valued at $4,981,000 after purchasing an additional 365,000 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.